About Second Sight
Second Sight is a company based in Los Angeles (United States) founded in 2000. Second Sight has raised $52.3 million across 23 funding rounds from investors including NIH and HHS. The company has 14 employees as of December 31, 2022. Second Sight has completed 1 acquisition, including Nano Precision Medical. Second Sight operates in a competitive market with competitors including Kodiak Sciences, Pixium Vision, Eyedaptic, iScience Interventional and Medical Instrument Development Laboratories, among others.
- Headquarter Los Angeles, United States
- Employees 14 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$52.3 M (USD)
in 23 rounds
-
Latest Funding Round
$1.1 M (USD), Grant
Jul 18, 2022
-
Investors
NIH
& 1 more
-
Employee Count
14
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Second Sight
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Second Sight
Second Sight has successfully raised a total of $52.3M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $1.1 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Second Sight
Second Sight has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Second Sight
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Second Sight
Second Sight has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nano Precision Medical.
Investment portfolio details for Second Sight
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Titanium capsule to provide constant rate delivery of therapeutic
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Second Sight
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Second Sight
Detailed financials for Second Sight
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Second Sight Comparisons
Peer comparison for Second Sight
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Second Sight
Second Sight operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kodiak Sciences, Pixium Vision, Eyedaptic, iScience Interventional and Medical Instrument Development Laboratories, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Bionic vision restoration systems are provided for sight restoration.
|
|
| Locked | Locked | Locked |
A wearable augmented reality vision assistance solution
|
|
| Locked | Locked | Locked |
Microcatheter and imaging technologies for ophthalmic procedures are developed.
|
|
| Locked | Locked | Locked |
Develops ophthalmic products for ophthalmic system manufacturers
|
Detailed competitors of Second Sight
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Second Sight
Complete news archive for Second Sight
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Second Sight
Second Sight was founded in 2000.
Second Sight is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Adam Mendelsohn is the current CEO of Second Sight.
Second Sight is a funded company, having raised a total of $52.3M across 23 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Second Sight is 14.
Provider of implantable visual prosthetics for blind individuals. The flagship product, Argus II Retinal Prosthesis System is an FDA and CE-approved device targeted for patients with severe to profound retinitis pigmentosa. Includes a miniature video camera housed in the patients glasses, a patient-worn computer where data is processed and transformed into instructions transmitted wirelessly to an antenna in the retinal implant. The implant emits electrical pulses which create perceptions of patterns of light. Patients learn to interpret these visual patterns with their retinal implant. It is also developing the Visual Cortical Prosthesis, Orion for blinds due to preventable or treatable conditions.
Second Sight's top competitors include Kodiak Sciences, Pykus Therapeutics and Pixium Vision.
Second Sight has made 1 acquisition, including Nano Precision Medical.